

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

SYH2053 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYH2053 Injection (double-stranded small interfering RNA (siRNA) drug) (the “**Product**”), a Class 1 chemical drug independently developed by the Group, has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trial in China.

The Product is an siRNA drug that achieves liver-targeted delivery through GalNAc conjugation, targeting PCSK9 for the treatment of primary hypercholesterolaemia or mixed dyslipidaemia in adults. It can achieve a more sustained gene silencing effect through an optimized full-sequence chemical modification strategy. In preclinical studies, the Product demonstrated a duration of pharmacological activity significantly longer than that of siRNA products of the same type, as well as good safety profile, providing a promising clinical development value. The Product is also the Group’s first siRNA product approved for clinical trials.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 30 November 2023

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.